More articles about Immunoassays

The FDA cleared the test to enable clinicians to provide better antibiotic treatment to patients with lower respiratory tract infections or sepsis.

The guidance recommends microsatellite instability testing or immunohistochemistry be used to detect abnormalities that may lead to Lynch syndrome. 

The company issued preliminary guidance for 2017 of $260 million to $275 million in revenues and adjusted EPS of between $.17 and $.22. 

The agency also cleared Roche's assay for diagnosing thyroid or pituitary disorders, as well as tests from Beckman Coulter, Immunostics, and BioMérieux. 

The test from Qiagen was able to identify young children with high interferon-gamma levels who later developed active disease.

The firm's medical business sales were down due to the timing of orders placed by distributors.